Comparative Pharmacology
Head-to-head clinical analysis: CYSTADANE versus ELCYS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYSTADANE versus ELCYS.
CYSTADANE vs ELCYS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Betaine acts as a methyl group donor in the remethylation of homocysteine to methionine, a reaction catalyzed by betaine-homocysteine methyltransferase. This reduces elevated homocysteine levels in homocystinuria.
ELCYS (eltrombopag olamine) is a small molecule agonist of the thrombopoietin receptor (TPO-R) on hematopoietic stem cells and megakaryocytes, activating JAK-STAT signaling to stimulate megakaryopoiesis and platelet production.
100 mg/kg/day orally divided into 3 doses, maximum 100 mg/kg/day; typical adult dose 6-9 g/day in divided doses.
100 mg orally three times daily
None Documented
None Documented
Cystadane (betaine anhydrous) has a terminal elimination half-life of approximately 14 hours (range 10-18 hours) following oral administration, supporting twice-daily dosing. The half-life is prolonged in patients with renal impairment.
Terminal elimination half-life is approximately 12-15 hours in adults with normal renal function; prolonged in renal impairment (up to 30 hours in severe cases).
Renal excretion of unchanged betaine accounts for less than 5% of the administered dose; metabolism occurs via demethylation to dimethylglycine, which is further metabolized to sarcosine and glycine. Metabolites are excreted renally. A small fraction may be eliminated in feces.
Primarily renal (approx. 35-50% unchanged drug) and biliary/fecal (about 50-60% as metabolites).
Category C
Category C
Amino Acid Supplement
Amino Acid Supplement